| Protocol | Title |
|---|---|
| 10104 | Phase III Randomized Double-Blind Study of Maintenance Therapy with
CC-5013 or Placebo Following Autologous Stem Cell Transplantation for
Multiple Myeloma
Activation Date: 18-jan-2006 |
| E1A05 | Randomized Phase III Trial of Consolidation Therapy with
Bortezomib(Velcade), CC-5013 & Dexamethasone(VRD) VS.
Bortezomib(Velcade) & Dexamethasone(VD) for Patients With Multiple
myeloma who have completed a Dexamethasone Based Induction Regimen.
Activation Date: 06-sep-2007 |
| E1A06 | An Intergroup Phase III Randomized Controlled Trial Comparing
Melphalan, Prednisone and Thalidomide (MPT) versus Melphalan,
Prednisone and Lenalidomide (Revlimid)(MPR) in Newly Diagnosed
Myeloma Patients Who Are Not Candidates for High Dose Therapy
Activation Date: 29-feb-2008 |
| E3A05 | Ancillary Laboratory Protocol for Collecting Diagnostic Material on
Patients Considered for Studies of Plasma Cell Disorders
Activation Date: 30-aug-2006 ECOG Participants(requires Adobe Acrobat) |
| JMY10 | A Randomized Phase III Study of Thalidomide and Prednisone as
Maintenance Therapy Following Autologous Stem Cell Transplant in
Patients with Multiple Myeloma
Activation Date: 16-dec-2005 |
| S0777 | A Randomized Phase III Trial of CC-5013 (Lenalidomide, NSC-703813 and
Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239),
Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in
Patients with Previously Untreated Multiple Myeloma without an Intent
for Immediate Autologous Stem Cell Transplant
Activation Date: 08-apr-2008 Suspended: 13-may-2008 |
All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 07/05/08